Hypofractionated Radiotherapy for Locally Advanced Non–Small Cell Lung Cancer—Does Size Matter?

To the Editor We would like to congratulate Dr Iyengar and colleagues for executing an important randomized clinical trial comparing 2 radiotherapy schedules for patients with stage II/III non–small cell lung cancer who are ineligible for concurrent chemoradiotherapy.¹ While the trial did not meet its primary end point, the study team has demonstrated the feasibility of a clinical trial in this patient population and generated important data to inform future efforts.